Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;44(2):140-152.
doi: 10.1111/aor.13551. Epub 2019 Sep 4.

Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity

Yassamine Bentata  1   2
Affiliations
Review

Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity

Yassamine Bentata. Artif Organs. 2020 Feb.

Abstract

Tacrolimus (or FK506), a calcineurin inhibitor (CNI) introduced in field of transplantation in the 1990s, is the cornerstone of most immunosuppressive regimens in solid organ transplantation. Its use has revolutionized the future of kidney transplantation (KT) and has been associated with better graft survival, a lower incidence of rejection, and improved drug tolerance with fewer side effects compared to cyclosporine. However, its monitoring remains complicated and underexposure increases the risk of rejection, whereas overexposure increases the risk of adverse effects, primarily nephrotoxicity, neurotoxicity, infections, malignancies, diabetes, and gastrointestinal complaints. Tacrolimus nephrotoxicity can be nonreversible and can lead to kidney graft loss, and its diagnosis is therefore best made with reference to the clinical context and after exclusion of other causes of graft dysfunction. Many factors contribute to its development including: systemic levels of tacrolimus; local renal exposure to tacrolimus; exposure to metabolites of tacrolimus; local susceptibility factors for CNI nephrotoxicity independent of systemic or local tacrolimus levels, such as the age of a kidney; local renal P-glycoprotein, local intestinal and hepatic cytochrome P450A3, and renin angiotensin system activation. The aim of this review is to describe the pharmacokinetics, pharmacodynamics, and mechanisms of acute and chronic tacrolimus nephrotoxicity in adult KT.

Keywords: acute; chronic; kidney; nephrotoxicity; tacrolimus; transplantation.

PubMed Disclaimer

References

REFERENCES

    1. Calne RY, Wood AJ. Cyclosporin in cadaveric renal transplantation: 3-year follow-up of a European multicentre trial. Lancet. 1985;2:549-52.
    1. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant. 2007;7 Pt 2:1359-75.
    1. Gao L, Xu F, Cheng H, Liu J. Comparison of sirolimus combined with tacrolimus and mycophenolate mofetil combined with tacrolimus in kidney transplantation recipients: a meta-analysis. Transplant Proc. 2018;50:3306-13.
    1. Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018;29:1979-91.
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-155.

MeSH terms

LinkOut - more resources